print version


Sweeney KJ, Jarzabek MA, Dicker P, O'Brien DF, Callanan JJ, Byrne AT*, Prehn JHM* "Validation of an Imageable Surgical Resection Animal Model of Glioblastoma (GBM)", J Neurosci Methods. 2014 Jun 18;233C:99-104. doi: 10.1016/j.jneumeth.2014.05.006


Jarzabek MA, Sweeney KJ, Evans RL, Jacobs AH, Stupp R, O'Brien D, Berger MS, Prehn JH, Byrne AT. Molecular imaging in the development of a novel treatment paradigm for glioblastoma multiforme: an integrated multidisciplinary commentary.Drug Discov Today. 2013 Jun 20. doi:pii: S1359-6446(13)00167-0. 10.1016/j. drudis. 2013. 06.004. [Epub ahead of print] PMID: 23792334 [PubMed - as supplied by publisher]


Jarzabek MA, Huszthy PC, Skaftnesmo KO, McCormack E, Dicker P, Prehn JH, Bjerkvig R, Byrne AT . In Vivo Bioluminescence Imaging Validation of a Human Biopsy-derived Orthotopic Mouse Model of Glioblastoma Multiforme . Mol Imaging 2013 12:1-12 PMID: 2013 (Mar 2013)

O'Connor S, Szwej E, Nikodinovic-Runic J, O'Connor A, Byrne AT, Devocelle M, O'Donovan N, Gallagher WM, Babu R, Kenny ST, Zinn M, Zulian QR, O'Connor KE . The anti-cancer activity of a cationic anti-microbial peptide derived from monomers of polyhydroxyalkanoate. Biomaterials. 2013 Apr 34(11):2710-8 PMID: PubMed PMID: 23343631 (Jan 2013)

Vader P, van der Meel R, Symons MH, Fens MH, Pieters E, Wilschut KJ, Storm G, Jarzabek M, Gallagher WM, Schiffelers RM, Byrne AT. (2011). Examining the Role of Rac1 in Tumour Angiogenesis and Growth: A clinically Relevant RNAi-mediated Approach. Angiogenesis 2011 Dec;14(4):457-66. Epub 2011 Jul 26. PubMed PMID: 21789714


van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G, Gallagher WM, Byrne AT. (2011). The VEGF/Rho GTPase signalling pathway: a promising target for antiangiogenic and anti-invasion therapy. Drug Discov Today, 16(5-6), 219-28 Epub 2011 Jan 22. Review. PubMed PMID: 21262381


O'Connor AE, Mc Gee MM, Likar Y, Ponomarev V, Callanan JJ, O'shea DF, Byrne AT, Gallagher WM. Mechanism of cell death mediated by a BF2-chelated tetraaryl-azadipyrromethene photodynamic therapeutic: dissection of the apoptotic pathway in vitro and in vivo. Int J Cancer. 2012 Feb 1;130(3):705-15. doi: 10.1002/ijc.26073. Epub 2011 May 26. PubMed PMID: 21413012.


O'Donovan N, Byrne AT, O'Connor AE, McGee S, Gallagher WM, Crown J. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells. Invest New Drugs. 2011 Oct;29(5):752-9. Epub 2010 Mar 16. PubMed PMID: 20229355.


Hams E, Saunders SP, Byrne AT, Fallon PG. (2011). The Hydroxylase Inhibitor DMOG Attenuates Endotoxic Shock via Alternative Activation of Macrophages and IL-10 Production by B-1 cells. Shock, In Press.


Fitzpatrick SF, Tambuwala MM, Bruning U, Schaible B, Scholz CC, Byrne A, O'Connor A, Gallagher WM, Lenihan CR, Garvey JF, Howell K, Fallon PG, Cummins EP. (2010). An intact canonical NF-κB pathway is required for inflammatory gene expression in response to hypoxia. J Immunol, 186(2), 1091-6.


Dekker J, Beekman AT, Boenink AD, Bomhof-Roordink H, Braamse AM, Collette EH, Huijgens PC, van der Linden MH, van Meijel B, Snoek FJ, Visser O, Verheul HM. Comment on 'Psychological distress in patients with cancer: is screening the effective solution?' Br J Cancer. 2013 Jun 11. doi: 10.1038/bjc.2013.286.

Ligthart-Melis GC, Weijs PJ, Te Boveldt ND, Buskermolen S, Earthman CP, Verheul HM, de Lange-de Klerk ES, van Weyenberg SJ, van der Peet DL. Dietician-delivered intensive nutritional support is associated with a decrease in severe postoperative complications after surgery in patients with esophageal cancer.Dis Esophagus. 2012 Dec 13. doi: 10.1111/dote.12008.

Westgeest HM, van Erp NP, Honeywell RJ, Hoekstra R, Peters GJ, Verheul HM. Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure. J Clin Oncol. 2013 Feb 20;31(6):e83-6. doi: 10.1200/JCO.2012.43.6485.

de Wit M, Fijneman RJ, Verheul HM, Meijer GA, Jimenez CR. Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications.Clin Biochem. 2013 Apr;46(6):466-79.

Giovannetti E, Labots M, Dekker H, Galvani E, Lind JS, Sciarrillo R, Honeywell R, Smit EF, Verheul HM, Peters GJ. Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells. Curr Pharm Des. 2013;19(5):927-39.

Hadj JO, Braven RD, Tillier C, Schrijver HM, Verheul HM, VAN DER Vliet HJ. Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma.Oncol Lett. 2012 Jun;3(6):1293-1296.

Buskermolen S, Langius JA, Kruizenga HM, Ligthart-Melis GC, Heymans MW, Verheul HM. Weight loss of 5% or more predicts loss of fat-free mass during palliative chemotherapy in patients with advanced cancer: a pilot study.

Kleibeuker EA, Griffioen AW, Verheul HM, Slotman BJ, Thijssen VL. Combining angiogenesis inhibition and radiotherapy: a double-edged sword. Drug Resist Updat. 2012 Jun;15(3):173-82. doi: 10.1016/j.drup.2012.04.002.

Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serné EH, Lammertsma AA,Smit EF (2012) Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs Cancer cell, 21(1), 82-91. PMID 22264790

Schneiders FL, de Bruin RC, van den Eertwegh AJ, Scheper RJ, Leemans CR, Brakenhoff RH, Langendijk JA, Verheul HM, de Gruijl TD, Molling JW, van der Vliet HJ (2012) Circulating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: updated analysis with 10-year follow-up, J Clin Oncol, 30(5), 567-570 PMID 22253469


Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, Griffioen AW, Assaraf YG, Pili R, Peters GJ, Verheul HM (2011) Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance, Clin Cancer Res 17(23), 7337-7346 PMID 21980135


Nilsson RJ, Balaj L, Hulleman E, van Rijn S, Pegtel DM, Walraven M, Widmark A, Gerritsen WR, Verheul HM, Vandertop WP, Noske DP, Skog J, Würdinger T (2011) Blood platelets contain tumor-derived RNA biomarkers Blood 118(13) 3680-3683 PMID 21832279


Walraven M, Witteveen PO, Lolkema MP, van Hillegersberg R, Voest EE, Verheul HM (2011) Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review, Angiogenesis 14(2), 135-141 PMID 21188500


Schneiders FL, van den Berg HP, Peters GJ, Verheul HM, van der Vliet HJ (2011) Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin, Med Oncol 28(4), 1136-1139 PMID 20567941


Piersma SR, Labots M, Verheul HM, Jiménez CR (2010) Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods Anal Bioanal Chem 397(8), 3163- 3171 PMID 20526883


Lynn MA, O'Hurley G, Balint B, Alamanou M, Coyle A, Gallagher WM. Biomarkers in Drug Discovery and Development. Encyclopedia of Pharmaceutical Science and Technology 4th Edition (2012).


Denecker G, Vandamme N, Akay Ö, Koludrovic D, Taminau J, Lemeire K, Gheldof A, De Craene B, Van Gele M, Brochez L, Udupi GM, Rafferty M, Balint B, Gallagher WM, Ghanem G, Huylebroeck D, Haigh J, van den Oord J, Larue L, Davidson I, Marine J-C, Berx G. Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death and Differentiation 2014 Apr 25. doi: 10.1038/cdd.2014.44


Mariette Labots, Lisette M. Schütte, Johannes C. van der Mijn, Thang V. Pham, Connie R. Jiménez, Henk M.W. Verheul Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies. The Oncologist, in press

Jimenez CR, Verheul HM. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications. Am Soc Clin Oncol Educ Book.

2014:e504-10. doi: 10.14694/EdBook_AM.2014.34.e504.


Blauwhoff-Buskermolen S, de van der Schueren MA, Verheul HM, Langius JA. 'Pre-cachexia': a non-existing phenomenon in cancer? Ann Oncol. 2014 Aug;25(8):1668-9. doi: 10.1093/annonc/mdu178. Epub 2014 May 14.


Koldenhof JJ, Witteveen PO, de Vos R, Walraven M, Tillier CN, Verheul HM, Teunissen SC. Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions. Support Care Cancer. 2014 Sep;22(9):2371-80. doi: 10.1007/s00520-014-2223-2. Epub 2014 Apr 2. PMID: 24687539


Versteeg KS, Konings IR, Lagaay AM, van de Loosdrecht AA, Verheul HM. Prediction of treatment-related toxicity and outcome with geriatric assessment in elderly patients with solid malignancies treated with chemotherapy: a systematic review. Ann Oncol. 2014 Apr 8. PMID: 24569912


Neefjes EC, van der Vorst MJ, Blauwhoff-Buskermolen S, Verheul HM.Aiming for a better understanding and management of cancer-related fatigue. Oncologist. 2013;18(10):1135-43. doi: 10.1634/theoncologist.2013-0076. PMID:24037979